Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin

Journal of the National Cancer Institute
R G Kilbourn, P Belloni

Abstract

Clinical studies using biological response modifiers in cancer therapy have shown that the major dose-limiting toxic effects are hypotension and diffuse microvascular leakage. The cause and pathophysiology of this hypotension remains unknown. Previous experiments have demonstrated that a number of cell types, including endothelial cells, neutrophils, and macrophages, can secrete a potent hypotensive agent--endothelium-derived relaxing factor, which has recently been identified as nitric oxide. In this study, we tested interferon gamma, tumor necrosis factor, interleukin-1, interleukin-2, muramyl dipeptide, and endotoxin for their effects on production of nitrogen oxides by endothelial cells. Interferon gamma, in combination with tumor necrosis factor, interleukin-1 (IL-1), or endotoxin, induced murine brain endothelial cells to secrete nitrites (20-45 microM within 48 hr), which are breakdown products of nitric oxide. Nitrite production was blocked by incubation of endothelial cells in medium without L-arginine, a substrate for nitric-oxide synthase. Accumulation of nitrites was also inhibited by addition of NG-monomethyl-L-arginine (L-NMMA), which acts as a competitive inhibitor of this enzyme. The inhibitory effects of L-NMMA...Continue Reading

Citations

Sep 10, 1998·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·B FernandoK Moore
Oct 15, 1993·Journal of Neuroscience Research·A M Morin, A Stanboli
May 1, 1995·Stem Cells·K BendtzenM Svenson
Jan 1, 1992·Cancer Immunology, Immunotherapy : CII·K Ryoyama
May 20, 1998·Biotherapy·R P Revoltella
Jan 6, 1999·Archives of Pharmacal Research·J H RyuY N Han
Feb 24, 2006·Journal of Cancer Research and Clinical Oncology·G V GirishA Kumar Sinha
Nov 30, 1993·European Journal of Pharmacology·C SzabóJ R Vane
Apr 1, 1995·Respiration Physiology·E S NozikC A Piantadosi
Dec 1, 1994·Immunology Letters·K Bendtzen
Nov 1, 1991·Trends in Pharmacological Sciences·N J Rothwell
Apr 1, 1993·Immunology Today·F BurkeF Balkwill
Jan 1, 1994·Parasitology Today·I A Clark, K A Rockett
Apr 1, 1996·General Pharmacology·M R Bennett, K R Huxlin
Sep 1, 1991·Research in Immunology·G Werner-FelmayerH Wachter
Aug 3, 1994·European Journal of Pharmacology·C van den BergD J de Wildt
Feb 11, 1991·Current Opinion in Immunology·C F Nathan, J B Hibbs
Jan 1, 1995·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J WagstaffC E Hack
Feb 13, 2004·Biological Psychiatry·Thayne L SweetenChristopher J McDougle
May 12, 2005·Clinical Biochemistry·Ayşe BalatYavuz Coşkun
May 1, 1997·Disease-a-month : DM·R G KilbournC Szabó
Sep 24, 1998·Transplantation Proceedings·K P PlatzP Neuhaus
May 1, 1996·The Journal of Infection·K A RockettI A Clark
Jul 31, 2003·Pharmacology & Therapeutics·Ian A Clark, William B Cowden

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.